Globus Medical (GMED) Tops Q1 EPS by 12c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Globus Medical (GMED) PT Raised to $73 at Stifel
May 5, 2021 9:36 AM EDTStifel analyst Mathew Blackman raised the price target on Globus Medical (NYSE: GMED) to $73.00 (from $60.00) while maintaining a Hold rating.
The analyst commented, "We expected GMED to post a strong 1Q, but the company's near-20% growth -- despite meaningful, early 1Q COVID... More
Globus Medical (GMED) PT Raised to $82 at Needham & Company
May 5, 2021 6:25 AM EDTNeedham & Company analyst Mike Matson raised the price target on Globus Medical (NYSE: GMED) to $82.00 (from $75.00) while maintaining a Buy rating.
The analyst commented, "GMED beat consensus revenue by 16% and EPS by 32% in 1Q21 driven by strong robotics implant pull-through, competitive rep hiring, new products,... More
